Endocrinology

Your Article Summary

See Latest Articles

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Favia G et al. – ONJ is a harmful side effect of bisphosphonate therapies. Clinicians must be aware of this entity, inform patients of the risks related to dental surgery, and possibly undertake adequate preventive measures.

• Over 4 year period, total of 102 bisphosphonate-treated patients affected by ONJ identified
• 24 patients underwent bisphosphonate therapy for non-neoplastic disease and profile analyzed

• In study cohort, bisphosphonates administered mainly for postmenopausal osteoporosis (20/24 patients, 83.3%)
• Duration of therapy until presentation of ONJ ranging from 11 to 40 months
• Most common triggering event dentoalveolar surgery
• All patients nonsmokers
• 6 manifested multiple ONJ lesions
• 3 had possible comorbidities
• Surgical debridement performed in 19 patients for total of 22 lesions, which were individually considered in followup
• Latter showed complete remission of ONJ in 21/22 lesions

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09

Risk factors for osteoporosis in healthy males
Central European Journal of Medicine, 11/25/09

Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women: The Japanese Population-based Osteoporosis (JPOS) Cohort Study
Osteoporosis International, 11/25/09

 See all of Bone Metabolism